TY - JOUR
T1 - An in vitro method of alcoholic liver injury using precision-cut liver slices from rats
AU - Klassen, Lynell Warren
AU - Thiele, Geoffrey Milton
AU - Duryee, Michael J.
AU - Schaffert, Courtney S.
AU - DeVeney, Amy L.
AU - Hunter, Carlos D.
AU - Olinga, Peter
AU - Tuma, Dean J.
N1 - Funding Information:
Supported by: National Institutes of Health Grants R01 AA10435, R37 AA07818, and R21 AA15505-01A2. Also supported by the Department of Veterans Affairs National Merit Review Program and the Department of Internal Medicine at the UNMC.
Funding Information:
We thank the members of the Experimental Immunology Laboratory at the Omaha VA Medical Center including, Karen C. Easterling, Bartlett C. Hamilton III, and Kristin M. Lenczowski. This material is based upon work supported (or supported in part) by the Office of Research and Development Medical Research Service, Department of Veterans Affairs.
PY - 2008/8/1
Y1 - 2008/8/1
N2 - Alcohol abuse results in liver injury, but investigations into the mechanism(s) for this injury have been hampered by the lack of appropriate in vitro culture models in which to conduct in depth and specific studies. In order to overcome these shortcomings, we have developed the use of precision-cut liver slices (PCLS) as an in vitro culture model in which to investigate how ethanol causes alcohol-induced liver injury. In these studies, it was shown that the PCLS retained excellent viability as determined by lactate dehydrogenase and adenosine triphosphate (ATP) levels over a 96-h period of incubation. More importantly, the major enzymes of ethanol detoxification; alcohol dehydrogenase, aldehyde dehydrogenase, and cytochrome P4502E1, remained active and PCLS readily metabolized ethanol and produced acetaldehyde. Within 24 h and continuing up to 96 h the PCLS developed fatty livers and demonstrated an increase in the redox state. These PCLS secreted albumin, and albumin secretion was decreased by ethanol treatment. All of these impairments were reversed following the addition of 4-methylpyrazole, which is an inhibitor of ethanol metabolism. Therefore, this model system appears to mimic the ethanol-induced changes in the liver that have been previously reported in human and animal studies, and may be a useful model for the study of alcoholic liver disease.
AB - Alcohol abuse results in liver injury, but investigations into the mechanism(s) for this injury have been hampered by the lack of appropriate in vitro culture models in which to conduct in depth and specific studies. In order to overcome these shortcomings, we have developed the use of precision-cut liver slices (PCLS) as an in vitro culture model in which to investigate how ethanol causes alcohol-induced liver injury. In these studies, it was shown that the PCLS retained excellent viability as determined by lactate dehydrogenase and adenosine triphosphate (ATP) levels over a 96-h period of incubation. More importantly, the major enzymes of ethanol detoxification; alcohol dehydrogenase, aldehyde dehydrogenase, and cytochrome P4502E1, remained active and PCLS readily metabolized ethanol and produced acetaldehyde. Within 24 h and continuing up to 96 h the PCLS developed fatty livers and demonstrated an increase in the redox state. These PCLS secreted albumin, and albumin secretion was decreased by ethanol treatment. All of these impairments were reversed following the addition of 4-methylpyrazole, which is an inhibitor of ethanol metabolism. Therefore, this model system appears to mimic the ethanol-induced changes in the liver that have been previously reported in human and animal studies, and may be a useful model for the study of alcoholic liver disease.
KW - Acetaldehyde
KW - Alcoholic liver disease
KW - Ethanol metabolism
KW - Fatty liver
KW - Precision-cut liver slice
UR - http://www.scopus.com/inward/record.url?scp=46849103206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46849103206&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2008.05.012
DO - 10.1016/j.bcp.2008.05.012
M3 - Article
C2 - 18599023
AN - SCOPUS:46849103206
SN - 0006-2952
VL - 76
SP - 426
EP - 436
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 3
ER -